Yoon K. Park
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
No more LAGging behind PD-1: uncovering the unique role of LAG-3 in T-cell exhaustion.
Journal: Cellular & molecular immunology
Published: September 25, 2024
Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.
Journal: Experimental & molecular medicine
Published: April 30, 2024
A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 27, 2023
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 07, 2022
Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells.
Journal: Cancer letters
Published: February 05, 2021
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 31, 2021
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy.
Journal: Cancer immunology research
Published: November 07, 2019
Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: July 29, 2019
Ultraviolet B activated 1,25(OH)(2)D affects the level of fibroblast growth factor-23 in human.
Journal: Endocrine journal
Published: September 19, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026